Equibles does not estimate personal net worth.
Get an email with a short summary when Regeneron Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get REGN alertsGeorge D. Yancopoulos, M.D., Ph.D. is recorded as Chairman at Regeneron Pharmaceuticals, Inc. (REGN) since April 17, 2023. Regeneron Pharmaceuticals, Inc. reported in an 8-K filed April 17, 2023 that George D. Yancopoulos, M.D., Ph.D. was appointed Co-Chair of the Board. George D. Yancopoulos, M.D., Ph.D. has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on June 12, 2026. Regeneron Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Regeneron Pharmaceuticals, Inc. includes Leonard S. Schleifer, M.D., Ph.D. (Chairman), Joseph J. LaRosa (General Counsel), Christine A. Poon (Board Member) and 7 others.
“Effective upon the expiration of Dr. Vagelos’s term, the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board (in addition to Dr. Schleifer’s and Dr. Yancopoulos’s continued roles as President and Chief Executive Officer and President and Chief Scientific Officer, respectively) and to designate Christine A. Poon as the Lead Independent Director of the Board.”
“A Regeneron Pharmaceuticals and President and Chief meeting format, as they would at an in-person meeting.”
“I'll start with our differentiated approach to treating complement-mediated diseases, which was highlighted last week at our latest Regeneron Roundtable Investor event.”
2023-04-17–present
Biotechnology · Healthcare
Chairman
2023-04-17–present
